Acta Scientific Paediatrics (ISSN: 2581-883X)

Research Article Volume 5 Issue 1

Vaccination for Covid-19 and Human Papillomavirus: A Comparative Study

Jitendar Sharma1, Umesh Gupta2, Pudi Nagaseshu3*, Kavita Kachroo4 and Greeshma Gopalan5

1MD & CEO/ ED, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India
2Professor, Head of Mats School of Business Studies, MATS Institute of Management and Entrepreneurship, Bangalore, India
3Scientist- C, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India
4Scientist- D, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India 5Scientist- A, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India

*Corresponding Author: Pudi Nagaseshu, Scientist- C, Kalam Institute of Health Technology, Andhra Pradesh Med Tech Zone, Visakhapatnam, India.

Received: November 25, 2021; Published: December 29, 2021


Introduction:  This review focused on two scenarios like HPV vaccination and Covid-19 vaccination. In the First scenario Covid 19 Vaccinations are known to boost immune system and it acts as a shield which fight against virus. In India Bharat Biotech in collaboration with the Indian Council of Medical Research had developed a vaccine Covaxin. The importance of covid-19 vaccination is to avoid severity and deaths from corona virus. Although, HPV vaccine and Covid 19 vaccines are different from each other and they are different in formulations affect and their usage, storage and type of administration, they are to be safe and effective. Hence, this article focusses on both covid 19 and HPV vaccination showing difference in costing, lives saved and budgetary impact. In the second scenario the importance of HPV vaccine is it protects against certain types of HPV that can lead to genital warts or cancer. In 2019 National immunization programs have been implemented in 124 countries and thus most of the girls and women were vaccinated by preventing cervical cancer.

Results and Discussion: Vaccines are saving millions of lives each year and they are most reliable and cost-effective for public health interventions. The efficacy of different Covid -19 vaccination m-RNA-1273 (70.4%), AstraZeneca (78%), Sinovac (94.5), Sputnik (91.4), Covaxin (81%), Covishiled (90%), m-RNA-BNT162B2 (94.1%). Gardasil has 98% efficacy and the efficacy of Cervarix is 91%.

 Conclusion: The efficacy of Covid 19 vaccination saves lives and 2,07,421 lives saved correspond to 1,506,501 QALYs gained for covid 19. Total Lives saved by HPV vaccination for 9 to 14-year-old is lesser than 42, 000 annually.

Keywords: Covid-19; Cervical Cancer; Vaccination; Lives Saved and HPV Types


  1. Kramer A., et al. “How long do nosocomial pathogens persist on inanimate surfaces: A systematic review”. BMC Infectious Disease 6 (2006): 130.
  2. Hui D., et al. “The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: The latest 2019 novel coronavirus outbreak in Wuhan, China”. International Journal of Infectious Diseases 91 (2020): 264-266.
  3. Gorbalenya A., et al. “Severe acute respiratory syndrome-related coronavirus: the species and its viruses - a statement of the Coronavirus Study Group”. BioRxiv (2020).
  4. Rismanbaf A. “Potential Treatments for COVID-19 a Narrative Literature Review”. Archives of Academic Emergency Medicine 8 (2020): e29.
  5. David F., et al. “Global Burden of Human Papillomavirus and Related Diseases”. Vaccine 5 (2012): F12-F23.
  6. Jan M., et al. “Introducing HPV Vaccine in Developing Countries: Key Challenges and Issues”. The New England Journal of Medicine (2007): 356:19.
  7. Barken S., et al. “Frequency of cervical intraepithelial neoplasia treatment in a well-screened population”. International Journal of Cancer 130 (2012): 2438-2444.
  8. Carter J., et al. “HPV infection and cervical disease: a review”. Australian and New Zealand Journal of Obstetrics and Gynaecology 51 (2011): 103-108.
  9. Clifford G., et al “HPV type-distribution in women with and without cervical neoplastic diseases”. Vaccine (2006). S26-S34.
  10. Munoz N., et al. “Epidemiologic classification of human papillomavirus types associated with cervical cancer”. The New England Journal of Medicine (2003): 518-527.
  11. De Martel C., et al. “Global burden of cancers attributable to infections in 2008: A review and synthetic analysis”. Lancet Oncology 13 (2012): 607-615.
  12. Shankar P., et al. “Cost-Effectiveness of Human Papillomavirus Vaccination for Adolescent Girls in Punjab State: Implications for India’s Universal Immunization Program”. Cancer17 (2017): 3253-3260.
  13. Koutsky L., et al. “A controlled trial of a human papillomavirus type 16 vaccine”. New England Journal of Medicine 21 (2002): 1645-1651.
  14. Arnold H., et al. “COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey”. Vaccines (2021).
  15. Mark J., et al. “Potential lives saved in 73 countries by adopting multi‐cohort vaccination of 9-14‐year‐old girls against human papillomavirus”. International Journal of Cancer (2018): 317-323.
  16. Akashdeep S., et al. “Cost effectiveness of strategies for cervical cancer prevention in India”. Plos One9 (2020): e0238291.
  17. Michael H., et al. “COVID-19 Vaccination Efficacy and Safety Literature Review”. Journal of Clinical and Medical Research (2020).
  18. Speiser D., et al. “COVID-19: Mechanisms of vaccination and immunity”. Vaccines 3 (2020): 404.
  19. Baden L., et al. “Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine”. New England Journal of Medicine 5 (2021): 403-416.
  20. Marc B., et al. “Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries”. Lancet 10224 (2020): 575-590.


Citation: Pudi Nagaseshu., et al. “Vaccination for Covid-19 and Human Papillomavirus: A Comparative Study”. Acta Scientific Paediatrics 5.1 (2022): 09-13.


Copyright: © 2022 Pudi Nagaseshu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is March 30, 2023.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US